Browsing Tag
UGN-102
1 post
Breakthrough for recurrent bladder cancer: UroGen’s UGN-102 achieves 80.6% 18-month complete response in phase 3 trial
Discover how UroGen Pharma’s UGN-102 could transform bladder cancer treatment with durable results; find out what the Phase 3 ENVISION trial reveals!